Current immunotherapeutic targets in gliomas
Publication
, Journal Article
Chandramohan, V; Mitchell, DA; Gromeier, M; Sampson, JH; Bigner, DD
May 1, 2013
The prospect for high-grade astrocytic tumor patients continues to be dismal, evenwith advances in surgery, radiotherapy, and chemotherapy. There is a need for thedevelopment of novel therapies that would eliminate the heterogeneous and diffuseastrocytic tumor cells.Innovative therapeutic approaches for the treatment of central nervous systemneoplasia, such as antibody-mediated immunotherapeutics, cellular immunotherapeutics,and oncolytic viruses targeting tumor-associated antigens, have emerged during the pastfew years.Herein we review several of the glioma-associated antigens and the current status ofimmunotherapeutics and oncolytic viruses targeting these antigens. © 2013 Nova Science Publishers, Inc. All rights reserved.
Duke Scholars
Publication Date
May 1, 2013
Start / End Page
287 / 305
Citation
APA
Chicago
ICMJE
MLA
NLM
Chandramohan, V., Mitchell, D. A., Gromeier, M., Sampson, J. H., & Bigner, D. D. (2013). Current immunotherapeutic targets in gliomas, 287–305.
Chandramohan, V., D. A. Mitchell, M. Gromeier, J. H. Sampson, and D. D. Bigner. “Current immunotherapeutic targets in gliomas,” May 1, 2013, 287–305.
Chandramohan V, Mitchell DA, Gromeier M, Sampson JH, Bigner DD. Current immunotherapeutic targets in gliomas. 2013 May 1;287–305.
Chandramohan, V., et al. Current immunotherapeutic targets in gliomas. May 2013, pp. 287–305.
Chandramohan V, Mitchell DA, Gromeier M, Sampson JH, Bigner DD. Current immunotherapeutic targets in gliomas. 2013 May 1;287–305.
Publication Date
May 1, 2013
Start / End Page
287 / 305